$RSPI
RespireRx Pharmaceuticals Inc. Stock $rspi

$rspi Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000149315222023726 Filed on August 22, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$250.9K	$211.4K	$495.8K
YoY Change	-40.76%	-50.4%	-23.18%
% of Gross Profit
Research & Development	$138.1K	$141.1K	$121.2K
YoY Change	-12.49%	-40.67%	-21.71%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$389.0K	$352.5K	$617.0K
YoY Change	-33.09%	-46.92%	-22.89%
Operating Profit	-$389.0K	-$352.5K	-$617.0K
YoY Change	-33.09%	-46.92%
Interest Expense	-$12.45K	-$127.8K	-$243.2K
YoY Change	-93.44%	-13.76%	385.35%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$472.6K	-$480.3K	-$860.2K
YoY Change	-33.32%	-40.87%	1.17%
Income Tax
% Of Pretax Income
Net Earnings	-$472.6K	-$480.3K	-$860.2K
YoY Change	-33.32%	-40.87%	1.17%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.01	-$0.01	-$0.01
Diluted Earnings Per Share	-$3.962K	-$4.528K	-$8.787K
COMMON SHARES
Basic Shares Outstanding	119.6M shares	106.1M shares	97.89M shares
Diluted Shares Outstanding	119.3M shares	106.1M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$60.00	$20.00	$250.00
YoY Change	-89.29%	-99.94%	-95.33%
Cash & Equivalents	$60.00	$21.00	$250.00
Short-Term Investments
Other Short-Term Assets	$50.54K	$77.69K	$103.1K
YoY Change	-77.97%	-29.63%	2.79%
Inventory
Prepaid Expenses	$50.54K	$77.69K
Receivables
Other Receivables
Total Short-Term Assets	$50.60K	$77.71K	$103.3K
YoY Change	-78.0%	-45.45%	-2.18%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$0.00	$0.00	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$50.60K	$77.71K	$103.3K
Total Long-Term Assets	$0.00	$0.00	$0.00
Total Assets	$50.60K	$77.71K	$103.3K
YoY Change	-78.0%	-45.45%	-2.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.751M	$5.586M	$5.479M
YoY Change	13.7%	8.71%	8.14%
Accrued Expenses	$3.131M	$2.969M	$2.789M
YoY Change	29.97%	39.27%	44.18%
Deferred Revenue
YoY Change
Short-Term Debt	$2.555M	$2.420M	$2.439M
YoY Change	37.7%	43.28%	56.45%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$11.44M	$10.98M	$10.71M
YoY Change	22.68%	22.5%	25.08%
LONG-TERM LIABILITIES
Long-Term Debt	$204.0K	$234.0K	$264.0K
YoY Change	-38.55%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$204.0K	$234.0K	$264.0K
YoY Change	-38.55%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.44M	$10.98M	$10.71M
Total Long-Term Liabilities	$204.0K	$234.0K	$264.0K
Total Liabilities	$11.64M	$11.21M	$10.97M
YoY Change	20.57%	25.11%	28.17%
SHAREHOLDERS EQUITY
Retained Earnings	-$175.8M	-$175.3M
YoY Change
Common Stock	$119.6K	$117.1K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$11.59M	-$11.13M	-$10.87M
YoY Change
Total Liabilities & Shareholders Equity	$50.60K	$77.71K	$103.3K
YoY Change	-78.0%	-45.45%	-2.18%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$472.6K	-$480.3K	-$860.2K
YoY Change	-33.32%	-40.87%	1.17%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$69.94K	-$61.99K	-$23.13K
YoY Change	-37.58%	-84.57%	-91.94%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	69.97K	61.76K	21.99K
YoY Change	-13.13%	-85.58%	-92.45%
NET CHANGE
Cash From Operating Activities	-69.94K	-61.99K	-23.13K
Cash From Investing Activities
Cash From Financing Activities	69.97K	61.76K	21.99K
Net Change In Cash	30.00	-230.0	-1.140K
YoY Change	-100.1%	-100.86%	-125.22%
FREE CASH FLOW
Cash From Operating Activities	-$69.94K	-$61.99K	-$23.13K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0000849636
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2022Q2	us-gaap	Deferred Costs Current DeferredCostsCurrent		usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q2	RSPI	Deemed Dividend Associated With Most Favored Nation Provisions Of Convertible Notes DeemedDividendAssociatedWithMostFavoredNationProvisionsOfConvertibleNotes		usd
	RSPI	Deemed Dividend Associated With Most Favored Nation Provisions Of Convertible Notes DeemedDividendAssociatedWithMostFavoredNationProvisionsOfConvertibleNotes		usd
CY2021Q1	RSPI	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits		usd
	us-gaap	Share Based Compensation ShareBasedCompensation		usd
	RSPI	Research And Development Share Based Compensation ResearchAndDevelopmentShareBasedCompensation		usd
	RSPI	Gain On Warrant Exchange GainOnWarrantExchange		usd
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges		usd
	RSPI	Increase Decrease In Fees Paid With Shares Of Common Stock IncreaseDecreaseInFeesPaidWithSharesOfCommonStock		usd
	RSPI	Payment Of Fees Associated With Conversions Of Convertible Notes By Issuance Of Stock PaymentOfFeesAssociatedWithConversionsOfConvertibleNotesByIssuanceOfStock		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	RSPI	Amortization Of Deferred Financing Costs AmortizationOfDeferredFinancingCosts		usd
	RSPI	Insurance Policies InsurancePolicies		usd
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1		usd
	RSPI	Cashless Warrant Exercises CashlessWarrantExercises		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	1-16467
	dei	Entity Registrant Name EntityRegistrantName	RESPIRERX PHARMACEUTICALS INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	33-0303583
	dei	Entity Address Address Line1 EntityAddressAddressLine1	126 Valley Road
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite C
	dei	Entity Address City Or Town EntityAddressCityOrTown	Glen Rock
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07452
	dei	City Area Code CityAreaCode	(201)
	dei	Local Phone Number LocalPhoneNumber	444-4947
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	119594276	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1398	usd
CY2021Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	177883	usd
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	77687	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	29456	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	77708	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	208737	usd
CY2022Q2	us-gaap	Assets Assets	77708	usd
CY2021Q4	us-gaap	Assets Assets	208737	usd
CY2022Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	5586490	usd
CY2021Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	5235767	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2968808	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2608708	usd
CY2022Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	992716	usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	790153	usd
CY2022Q2	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	792748	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	837104	usd
CY2022Q2	RSPI	Notesand Advances Payableto Officers NotesandAdvancesPayabletoOfficers	345724	usd
CY2021Q4	RSPI	Notesand Advances Payableto Officers NotesandAdvancesPayabletoOfficers	230356	usd
CY2022Q2	RSPI	Notes Payable Former Officers Current NotesPayableFormerOfficersCurrent	215398	usd
CY2021Q4	RSPI	Notes Payable Former Officers Current NotesPayableFormerOfficersCurrent	205222	usd
CY2022Q2	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	73283	usd
CY2021Q4	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	15185	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	10975167	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9922495	usd
CY2022Q2	us-gaap	Due To Affiliate Noncurrent DueToAffiliateNoncurrent	234000	usd
CY2021Q4	us-gaap	Due To Affiliate Noncurrent DueToAffiliateNoncurrent	294000	usd
CY2022Q2	us-gaap	Accounts Payable Related Parties Noncurrent AccountsPayableRelatedPartiesNoncurrent	234000	usd
CY2021Q4	us-gaap	Accounts Payable Related Parties Noncurrent AccountsPayableRelatedPartiesNoncurrent	294000	usd
CY2022Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	234000	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	294000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	11209167	usd
CY2021Q4	us-gaap	Liabilities Liabilities	10216495	usd
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	21703	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	21703	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2000000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2000000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	117069276	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	117069276	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	97894276	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	97894276	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	117069	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	97894	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	164025356	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	163827781	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-175295587	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-173955136	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-11131459	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-10007758	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	77708	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	208737	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	211376	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	426169	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	707170	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1071545	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	141099	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	237828	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	262257	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	392592	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	352475	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	663997	usd
	us-gaap	Operating Expenses OperatingExpenses	969427	usd
	us-gaap	Operating Expenses OperatingExpenses	1464137	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-352475	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-663997	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-969427	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1464137	usd
CY2021Q2	RSPI	Gain Loss On Warrant Exchange GainLossOnWarrantExchange	1099	usd
	RSPI	Gain Loss On Warrant Exchange GainLossOnWarrantExchange	1099	usd
CY2022Q2	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	179521	usd
CY2021Q2	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	151842	usd
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	439169	usd
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	231312	usd
CY2022Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	51708	usd
CY2021Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	2526	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	68145	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	31887	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-480288	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-812214	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1340451	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1662463	usd
CY2022Q2	RSPI	Deemed Dividend Associated With Most Favored Nation Provisions Of Convertible Notes DeemedDividendAssociatedWithMostFavoredNationProvisionsOfConvertibleNotes	351738	usd
	RSPI	Deemed Dividend Associated With Most Favored Nation Provisions Of Convertible Notes DeemedDividendAssociatedWithMostFavoredNationProvisionsOfConvertibleNotes	351738	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-832026	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-812214	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1692189	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1662463	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106081803	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	89832860	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	102010657	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	82212945	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-10007758	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-860163	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-10867921	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	25000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	191750	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-480288	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-11131459	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-8063320	usd
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	117299	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	52609	usd
CY2021Q1	RSPI	Issuance Of Note Commitment Shares And Beneficial Conversion Feature IssuanceOfNoteCommitmentSharesAndBeneficialConversionFeature	97500	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	252511	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	44250	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-850249	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-8454618	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-8454618	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	7500	usd
CY2021Q2	RSPI	Gain On Warrant Exchange GainOnWarrantExchange	1099	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	443550	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-812214	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-8816881	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-8816881	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1340451	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1662463	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	336728	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	161589	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	36750	usd
	RSPI	Research And Development Share Based Compensation ResearchAndDevelopmentShareBasedCompensation	15000	usd
	RSPI	Gain On Warrant Exchange GainOnWarrantExchange	1099	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	68145	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	32255	usd
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-177883	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-47619	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	78744	usd
	RSPI	Increase Decrease In Fees Paid With Shares Of Common Stock IncreaseDecreaseInFeesPaidWithSharesOfCommonStock	-4000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	304382	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	214828	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	360100	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	590850	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	96762	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	62973	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-85122	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-688571	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	25000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	541050	usd
	RSPI	Payment Of Fees Associated With Conversions Of Convertible Notes By Issuance Of Stock PaymentOfFeesAssociatedWithConversionsOfConvertibleNotesByIssuanceOfStock	1500	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	117299	usd
	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	-37752	usd
	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	66453	usd
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	94997	usd
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-5000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	83745	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	719802	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1377	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	31231	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1398	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	825	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	21	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	32056	usd
	us-gaap	Interest Paid Net InterestPaidNet	5657	usd
	us-gaap	Interest Paid Net InterestPaidNet	2926	usd
	RSPI	Amortization Of Deferred Financing Costs AmortizationOfDeferredFinancingCosts	52609	usd
	RSPI	Insurance Policies InsurancePolicies	95850	usd
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	60000	usd
	us-gaap	Notes Reduction NotesReduction	25000	usd
	us-gaap	Notes Reduction NotesReduction	541040	usd
	RSPI	Debt And Accrued Interest Converted To Common Stock DebtAndAccruedInterestConvertedToCommonStock	190250	usd
	RSPI	Debt And Accrued Interest Converted To Common Stock DebtAndAccruedInterestConvertedToCommonStock	4000	usd
	RSPI	Cashless Warrant Exercises CashlessWarrantExercises	900	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	7500000	usd
CY2022Q2	us-gaap	Share Price SharePrice	0.02
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-480288	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1340451	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-832026	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1692189	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-85122	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-688571	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-956172	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-11131459	usd
CY2022Q2	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	100000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_842_eus-gaap--UseOfEstimates_zwO31IlJzRWl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zpwiMSBVfKi5">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include, among other things, accounting for potential liabilities, and the assumptions used in valuing stock-based compensation issued for services. Actual amounts may differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/> </p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_zydjD5I6tF8j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zjxW7bQbjUG2">Concentration of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company limits its exposure to credit risk by investing its cash with high quality financial institutions. The Company’s cash balances may periodically exceed federally insured limits. The Company has not experienced a loss in such accounts to date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	0	shares
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
	RSPI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instrument Weighted Average Exercise Price Expired ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePriceExpired	0.0160
	us-gaap	Intangible Assets Finite Lived Policy Costs Incurred To Renew Or Extend IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend	<p id="xdx_849_eus-gaap--IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_z4udBvpgwgEl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zUZXFAApDwE9">Patent Costs</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts and any related patent applications, all patent costs, including patent-related legal and filing fees, are expensed as incurred and recorded as general and administrative expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	186231560	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	79369694	shares
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_84F_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zYypR5qIMLR2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zLLRvWgfNt57">Reclassifications</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain comparative figures in 2021 have been reclassified to conform to the current quarter’s presentation. These reclassifications were immaterial, both individually and in the aggregate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	0.01
CY2022Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	0.01
CY2012Q2	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2013-06-25
CY2021Q2	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	10000	usd
CY2021Q3	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	75000	usd
CY2022Q1	us-gaap	Payments For Fees PaymentsForFees	415	usd
CY2017Q1	RSPI	Attorneys Fees And Cost AttorneysFeesAndCost	47937	usd
CY2022Q2	RSPI	Accured Interest AccuredInterest	35665	usd
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	RSPI	Preferred Stock Shares Undesignated PreferredStockSharesUndesignated	3504424	shares
CY2021Q4	RSPI	Preferred Stock Shares Undesignated PreferredStockSharesUndesignated	3504424	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2000000000	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	117069276	shares
CY2022Q2	us-gaap	Shares Issued SharesIssued	84923	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	59420298	shares
CY2021Q4	RSPI	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsWeightedAverageExercisePrice	0.0718
	RSPI	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Term Beginning SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning	P3Y3M29D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	36102800	shares
	RSPI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercise Price Issued ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceIssued	0.0100
	RSPI	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Term Issued SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermIssued	P4Y3M17D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	2212500	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	93310598	shares
CY2022Q2	RSPI	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsWeightedAverageExercisePrice	0.0472
	RSPI	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm	P2Y6M20D
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.0038
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	28809352	shares
CY2020Q4	RSPI	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsWeightedAverageExercisePrice	0.1528
	RSPI	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Term Beginning SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning	P2Y7M20D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	12561174	shares
	RSPI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercise Price Issued ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceIssued	0.02
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	8595	shares
	RSPI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instrument Weighted Average Exercise Price Expired ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePriceExpired	79.3000
	RSPI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exchanged ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged	1062500	shares
	RSPI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instrument Weighted Average Exercise Price Exchanged ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePriceExchanged	0.07
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	1665958	shares
	RSPI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercise Price Issued Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceIssuedExercised	0.02
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	38633473	shares
CY2021Q2	RSPI	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsWeightedAverageExercisePrice	0.1002
	RSPI	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm	P1Y9M10D
CY2021Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.0365
CY2021Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	12727148	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9306368	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.09
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y11M12D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	84923	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	41.04
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9221445	shares
CY2022Q2	RSPI	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1	0.73
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y8M26D
CY2022Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	9221445	shares
CY2022Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	9221445	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2000000000	shares
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	117069276	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9221445	shares
	RSPI	Debt Conversion Shares Issuable DebtConversionSharesIssuable	83699517	usd
CY2022Q2	RSPI	Class Of Warrant Or Right Outstanding Not Yet Occurred ClassOfWarrantOrRightOutstandingNotYetOccurred	93310598	shares
CY2022Q2	RSPI	Number Of Additional Contractual Reserves Shares NumberOfAdditionalContractualReservesShares	163430485	shares
CY2021Q3	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	75000	usd
CY2021Q3	RSPI	Agreement Expiration Date AgreementExpirationDate	2022-06-30
CY2021Q2	us-gaap	Contractual Obligation ContractualObligation	990877	usd
CY2022Q2	us-gaap	Contractual Obligation ContractualObligation	765577	usd
CY2022Q2	us-gaap	Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear	285392	usd
CY2022Q2	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	125093	usd
CY2022Q2	us-gaap	Contractual Obligation Due In Second Year ContractualObligationDueInSecondYear	125092	usd
CY2022Q2	us-gaap	Contractual Obligation Due In Third Year ContractualObligationDueInThirdYear	115000	usd
CY2022Q2	us-gaap	Contractual Obligation Due In Fourth Year ContractualObligationDueInFourthYear	115.0000	usd

Files In Submission

Name	View Source	Status
0001493152-22-023726-index-headers.html	Edgar Link	pending
0001493152-22-023726-index.html	Edgar Link	pending
0001493152-22-023726.txt	Edgar Link	pending
0001493152-22-023726-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rspi-20220630.xsd	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
Show.js	Edgar Link	pending
rspi-20220630_lab.xml	Edgar Link	unprocessable
rspi-20220630_pre.xml	Edgar Link	unprocessable
rspi-20220630_def.xml	Edgar Link	unprocessable
rspi-20220630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RSPI
RespireRx Pharmaceuticals Inc. Stock $rspi

2022 Q3 Form 10-Q Financial Statement

#000149315222023726 Filed on August 22, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RSPI RespireRx Pharmaceuticals Inc. Stock $rspi

2022 Q3 Form 10-Q Financial Statement

#000149315222023726 Filed on August 22, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RSPI
RespireRx Pharmaceuticals Inc. Stock $rspi